Post-Transplant Cytoxan
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 56 patients (estimated)
- Sponsors
- University of Minnesota - Masonic Cancer Center
- Tags
- Xanthine Oxidase Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1629
- NCT Identifier
- NCT05805605
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.